Table 3.

Sensitivity analyses for association between current longer-term use of any estrogen-plus-progestin therapy (CHT) or any estrogen therapy (ET) compared to never any use of hormone therapy (HT), and fatal breast cancer: Odds Ratios (OR) and 95% confidence intervals (95% CI). Women’s CARE Study. 1994–1998, Atlanta, Seattle, Los Angeles, Detroit, Philadelphia.

		Any CHT		Any ET
		N exposed* cases/controls	OR (95% CI)	N exposed* cases/controls	OR (95% CI)
A	Adjusted for age at menopause, type of menopause and screening, as presented in Table 2	32/301	0.94 (0.59, 1.48)	42/510	0.70 (0.45, 1.07)
B	A, also adjusted for <2 times federal poverty level for household income (y/n)	31/291	1.03 (0.64, 1.64)	40/495	0.73 (0.47, 1.13)
C	A, excluding women with unclassifiable menopausal status	10/86	1.16 (0.55, 2.42)	23/298	0.91 (0.47, 1.78)
D	A, but current longer-term use defined as 5+ years	24/220	1.00 (0.60, 1.66)	29/424	0.57 (0.35, 0.93)

^*Rows A–C: Current 3+ years of HT use, Row D: Current 5+ years of HT use